Interim FDG-PET does not predict outcome in advanced-stage Hodgkin lymphoma patients treated with BEACOPP

Affiliations

¹ Department of Radiology and Nuclear Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
² Department of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.

Comment

Hugo J A Adams et al. Br J Haematol. 2019 May.

. 2019 May;185(4):758-760.

doi: 10.1111/bjh.15602. Epub 2018 Nov 14.

¹ Department of Radiology and Nuclear Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
² Department of Radiology, Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.

No abstract available

Keywords: FDG-PET; Hodgkin lymphoma.

Comment on

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A. Borchmann P, et al. Lancet. 2017 Dec 23;390(10114):2790-2802. doi: 10.1016/S0140-6736(17)32134-7. Epub 2017 Oct 20. Lancet. 2017. PMID: 29061295 Clinical Trial.